Open AccessCamrelizumab (SHR-1210) leading to reactive capillary hemangioma in the gingiva: A case report
Author(s) -
Qing Yu,
Wenxia Wang
Publication year - 2020
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v8.i3.624
Subject(s) - medicine , gingival enlargement , scaling and root planing , hemangioma , capillary hemangioma , adverse effect , cancer , pathology , dentistry , periodontitis , chronic periodontitis
Oncologic immunotherapy is attracting attention as an effective strategy for cancer treatment. Currently, there are two kinds of inhibitors: Anti-PD-1 antibodies and anti-PD-L1 antibodies. These inhibitors have shown significant implications in improving the outcomes of certain cancer types in recent years. However, along with its effectiveness, adverse events cannot be ignored. As an anti-PD-1 antibody, camrelizumab (SHR-1210) has some side effects in tumor immunotherapy. The most common adverse event is reactive capillary hemangioma. While it is widely reported to occur in the skin, gingival reactive capillary hemangioma is rarely reported.